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Abstract
Albumin dialysis using the molecular adsorbent recirculating system (MARS) is a new therapeutic approach for liver
diseases. To gain insight into the mechanisms involved in albumin dialysis, we analyzed the peptides and proteins absorbed
into the MARS strong anion exchange (SAX) cartridges as a result of the treatment of patients with cholestasis and resistant
pruritus. Proteins extracted from the SAX MARS cartridges after patient treatment were digested with two enzymes. The
resulting peptides were analyzed by multidimensional liquid chromatography coupled to tandem mass spectrometry. We
identified over 1,500 peptide sequences corresponding to 144 proteins. In addition to the proteins that are present in
control albumin-derived samples, this collection includes 60 proteins that were specific to samples obtained after patient
treatment. Five of these proteins (neutrophil defensin 1 [HNP-1], secreted Ly-6/uPAR-related protein 1 [SLURP1], serum
amyloid A, fibrinogen alpha chain and pancreatic prohormone) were confirmed to be removed by the dialysis procedure
using targeted selected-reaction monitoring MS/MS. Furthermore, capture of HNP-1 and SLURP1 was also validated by
Western blot. Interestingly, further analyses of SLURP1 in serum indicated that this protein was 3-fold higher in cholestatic
patients than in controls. Proteins captured by MARS share certain structural and biological characteristics, and some of
them have important biological functions. Therefore, their removal could be related either to therapeutic or possible
adverse effects associated with albumin dialysis.
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Introduction
Extracorporeal albumin dialysis (ECAD) using the molecular
adsorbent recirculating system (MARS) has been used in patients
with acute-on-chronic liver failure or acute liver failure, and in the
treatment of primary graft dysfunction after liver transplantation
with favorable, although indefinite, results in terms of survival [1],
[2], [3], [4], [5], [6], [7], [8], [9]. Another application of MARS is
the treatment of resistant pruritus in chronic cholestatic diseases
and in patients with pruritus resulting from liver graft rejection
and severe cholestasis. In these latter conditions, the procedure is
effective in most patients after only two sessions. Furthermore,
albumin dialysis with MARS is well tolerated, and can therefore be
considered the last rescue step in patients with pruritus who did
not experience favorable results with non-invasive treatments.
MARS treatment can avoid liver transplantation in patients with
chronic cholestatic diseases who experience severe and unbearable
itching [8]. Many substances have been proposed as possible
causes of pruritus in cholestasis, including bile salts, steroids and
steroid metabolites, histamine and endogenous opioids. However,
none of these molecules have been shown to be pruritogens and
the pathogenesis of pruritus in cholestasis is still not firmly
established [10], [11], [12], [13].
The clinical effects of MARS are presumably due to the
removal of albumin-bound substances from the patient’s blood
[14], [15], [16]. However, the exact mechanism of MARS
function and the entire set of substances removed by MARS from
a patient’s blood remain unclear. Characterization of MARS-
captured molecules is hampered by their relatively low concen-
tration in the albumin matrix. In addition, the commercial human
serum albumin (HSA) that is used in the MARS circuit contains
many other proteins that interfere with the analysis. Recently, we
described more than 140 proteins in these preparations in addition
to albumin [17]. In MARS, the albumin-enriched dialysate, which
contains 20% human serum albumin, is recirculated. Albumin
binding sites are regenerated by online perfusion through a strong
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simultaneously dialyzed against a bicarbonate-buffered solution
using a standard dialysis machine or hemoperfusion.
In the present study, we used a shotgun proteomic approach
combined with targeted MS/MS procedures to describe the set of
peptides and proteins that were captured by the MARS system
from patients’ blood and absorbed in the SAX cartridges in
patients treated for resistant pruritus (Figure 1). Our aim was to
contribute to further understanding of the role of MARS and its
beneficial effects in patients with liver diseases.
Results
Peptide and protein identification
Parallel analysis by MDLC-ESIMS/MS of tryptic and GluC
(Staphylococcus aureus protease V8) digests of the MARS SAX
extracts led to the identification of a total of 1,726 distinct peptides
(FDR,1%). Proteins identified from only one peptide were re-
evaluated with PEAKS to avoid false positives. Only peptide
identifications that coincided in PEAKS and SEQUEST analyses
were considered. Using this approach, 1,538 peptides correspond-
ing to 144 proteins were identified with high confidence (Table S1
and Table S2). From the total set of proteins, 126 had at least one
peptide that was unique to its sequence. Eighty-four of the proteins
were detected in both the albumin control extract and the extract
obtained after patient treatment with MARS, while a further sixty
proteins were identified only in the patient-derived samples
(Table 1).
Selected reaction monitoring analysis
Twelve of the 60 proteins that were putatively derived from
patients were selected for targeted MS/MS analysis in control-
and patient-derived extracts. In addition, 5 proteins that were
common to both samples were taken as references (Table 2).
Targeted proteins were selected on the basis of their molecular
weight and the sequence coverage observed in previous experi-
ments. Thus, we selected proteins of low molecular mass
(,15 kDa) that were identified in both replicates with high
sequence coverage (.25%). An exception was made for the
fibrinogen alpha chain (98 kDa). Although this chain was larger
than the MARS membrane cutoff (50 KDa), we selected it as it
was identified from a high number of different peptides (58
peptides). This indicates that high amounts of this protein or, more
probably, fragments of the protein, are removed during the
MARS dialysis process.
Each targeted protein was monitored through up to four of its
previously detected tryptic peptides. These peptides were selected
to provide a collection of 34 peptide markers evenly distributed
throughout the chromatographic separation. Seventeen of the
targeted peptides that represent 10 different proteins were
effectively detected and measured by SRM analysis (Table 2).
These included five of the proteins that may have been removed
by dialysis and five reference proteins (Figure 2). The analyses
confirmed that the five candidates in the dialysates came from
patients. This set was composed of HNP-1, SLURP1, serum
amyloid A, fibrinogen alpha chain and pancreatic prohormone.
Validation by Western blot
The presence of HNP-1 and SLURP1 was assessed by Western
blot on SAX extracts from the five patients treated with MARS.
Alpha-1B-glycoprotein (A1BG), which was identified in control
and treated samples by MDLC-ESIMS/MS and SRM analysis,
was used as a control for the Western blot validation. In agreement
with the above-described mass spectrometry results, the presence
of HNP-1 was confirmed in all patient samples, but was not
detected in the control albumin sample. SLURP1 was not detected
in the control sample either. However, it was present in the SAX
extract from the four patients with resistant pruritus, but not in the
patient with Wilson’s disease (Figure 3).
SLURP1 serum levels in PBC patients and healthy controls
One of the SAX cartridge extracts analyzed in the previous
experiments was used as a SLURP1 positive control, and the
intensities of SLURP1 signals were normalized to this control
sample (Figure 4). SLURP1 was identified by Western blot in all
control subjects and 27 PBC patients, although the relative
concentration was significantly higher in patients (0.3260.04) than
in healthy controls (0.1060.02) (p,0.005, unpaired t-test, mean 6
standard error of the mean). Taking into account the highest level
observed in healthy subjects (0.203), 16 out of 27 patients (59%)
had high serum SLURP1 levels. SLURP1 was elevated in 9 of the
11 patients with pruritus (82%) and in 7 of the 12 patients without
pruritus (58%), but in none of the four patients with pruritus who
were treated with rifampicin.
Discussion
There is still little knowledge of the proteins and other biological
compounds that are removed from blood during albumin dialysis.
Most of the substances that are known to be removed are small
Figure 1. Analytical workflow. Proteins retained in the SAX resin are
extracted by stepwise elution. Two aliquots of these extracts are
digested with two different enzymes (trypsin and GluC, respectively)
and peptides identified by MDLC-ESIMS/MS. Target peptides were
confirmed by selected reaction monitoring. The identification of some
proteins as removed from patients’ blood (and not from the commercial
albumin solution used in the MARS circuit) was further validated by
Western blot.
doi:10.1371/journal.pone.0021850.g001
Peptides and Protein Captured by MARS
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21850Table 1. Data set of proteins captured by MARS.
Accesion #
(Uniprot)
Protein
Name
Mr
(KDa)
#
pep
Sequence
Coverage (%)
Accesion #
(Uniprot)
Protein
Name
Mr
(KDa)
#
pep
Sequence
Coverage (%)
P02671 Fibrinogen
alpha chain
95.0 58 32 O15091 Mitochondrial
ribonuclease P protein 3
67.3 2 10
P01833 Polymeric
immunoglobulin
receptor
83.3 17 6 Q9NP84 Tumor necrosis factor
receptor superfamily
member 12A
13.9 2 13
P06727 Apolipoprotein A-IV 45.4 14 30 O00264 Membrane-associated
progesterone receptor
component 1
21.7 2 12
P59666 Neutrophil defensin 3 10.2 10 58 Q8N2S1 Latent-transforming growth
factor beta-binding protein 4
173.4 2 3
P59665 Neutrophil
defensin 1
10.2 9 55 P28223 5-hydroxytryptamine
receptor 2A
52.6 2 7
P14209 CD99 antigen 18.8 7 35 P36955 Pigment epithelium-derived
factor
46.3 2 10
P10124 Serglycin 17.6 6 22 P18065 Insulin-like growth
factor-binding protein 2
35.1 2 8
P24593 Insulin-like growth
factor-binding protein 5
30.6 5 26 P60985 Keratinocyte differentiation-
associated protein
11.0 2 11
P10645 Chromogranin-A 50.7 5 14 P00747 Plasminogen 90.6 2 5
P01344 Insulin-like growth
factor II
20.1 5 23 P22692 Insulin-like growth factor-
binding protein 4
27.9 2 12
Q16610 Extracellular matrix
protein 1
60.7 4 12 O00533 Neural cell adhesion
molecule L1-like protein
135.0 2 3
P12111 Collagen alpha-3(VI) chain 343.7 4 1 P01298 Pancreatic prohormone 10.4 2 30
P81605 Dermcidin 11.3 4 25 Q15847 Adipose most abundant
gene transcript 2 protein
7.8 2 86
P55000 Secreted Ly-6/
uPAR-related protein 1
11.2 4 59 Q16661 Guanylate cyclase
activator 2B
12.1 2 19
P0C0L5 Complement C4-B 192.8 4 1 P22614 Putative serum
amyloid A-3 protein
13.4 1 13
P0C0L4 Complement C4-A 192.8 4 1 P04085 Platelet-derived growth
factor subunit A
24.0 1 8
P19022 Cadherin-2 99.8 3 6 Q9ULI3 Protein HEG homolog 1 147.4 1 0
Q96NZ9 Proline-rich acidic protein 1 17.2 3 21 P37837 Transaldolase 37.5 1 7
Q16627 C-C motif chemokine 14 10.7 3 58 Q16819 Meprin A subunit alpha 84.4 1 1
P08493 Matrix Gla protein 12.3 3 30 Q15063 Periostin 93.3 1 1
Q9UHG2 ProSAAS 27.4 3 7 P10451 Osteopontin 35.4 1 4
P02735 Serum amyloid A protein 13.5 3 29 P28335 5-hydroxytryptamine
receptor 2C
51.8 1 2
P07602 Proactivator polypeptide 58.1 3 7 P81172 Hepcidin 9.4 1 21
P00746 Complement factor D 27.0 3 14 P54710 Sodium/potassium-
transporting ATPase
gamma chain
7.3 1 21
P28799 Granulins 63.5 3 10 P35542 Serum amyloid A-4 protein 14.8 1 6
Q16663 C-C motif chemokine 15 12.2 3 31 P08123 Collagen alpha-2(I) chain 129.3 1 1
P30456 HLA class I
histocompatibility
antigen, A-43 alpha chain
41.0 1 4 Q9Y624 Junctional adhesion
molecule A
32.6 1 6
P35527 Keratin,typeIcytoskeletal9 62.1 2 5 P04118 Colipase 11.9 1 12
P02818 Osteocalcin 10.9 2 19 Q8N729 Neuropeptide W 18.0 1 10
P30512 HLA class I
histocompatibility
antigen, A-29 alpha chain
40.8 1 4 Q8TDB2 Transthyretin amyloidosis
variant D38V
4.8 16 60
doi:10.1371/journal.pone.0021850.t001
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Several proteins have also been reported to be removed by
MARS, including regulators of the inflammatory cascade (tumor
necrosis factor-a or interleukin-6) and hepatic growth factors
(hepatocyte growth factor or epidermal growth factor). These
molecules were identified in studies that analyzed their presence in
blood from patients and in the MARS albumin circuit before and
after perfusion through the SAX and charcoal cartridges and
measured their relative concentrations before and after dialysis
[15,16]. As far as we know, all these measurements were carried
out on molecules for which an ELISA, an RIA or an established
clinical assay was available. In this study, we performed a global
proteomic analysis of the molecules retained in the MARS SAX
cartridges, to characterize new peptides and proteins dialyzed
from patients’ blood. In addition, as many proteins are
concentrated in the SAX cartridges during dialysis, our procedure
could detect substances in low concentrations that may be difficult
to detect at serum levels or in the albumin circuit.
In preliminary experiments, the analysis of proteins absorbed in
the MARS cartridges during patient treatment was hampered by
the presence of many different proteins that were originally
present in the commercial albumin used for the MARS internal
circuit. These albumin solutions are industrially prepared from
human plasma by the Cohn process [18], which yields albumin of
about 95% purity. In a recent study of the composition of this
blood derivative, we identified a total of 141 proteins in addition to
albumin [17]. The set of proteins detected in these solutions could
result from their co-purification with HSA, due to their similar
physicochemical properties and/or their affinity for albumin.
Interestingly, almost 50% of these proteins have been described
previously as forming part of the albuminome [19,20].
To identify the proteins derived from patients after MARS
treatment in these complex albumin extracts, we followed an
approach consisting of a shotgun analysis followed by a targeted
MS/MS analysis. Molecules identified in the shotgun analysis that
had not been identified in control albumin-derived samples were
selected for the semi-quantitative targeted MS/MS analysis, in
which their presence/absence in control and patient-derived
samples was confirmed. For this purpose, we applied an SRM
method that provided a high-sensitivity procedure for monitoring
the target peptides (Figure 2, Table S3).
Overall, the number of peptides and proteins identified in the
analysis of patient-derived samples was similar to that reported in
the analysis of control albumin [17]. However, the ratio of non-
canonically to canonically-terminated peptides in the patient-
derived extracts was twice as high as the corresponding ratio in
control albumin (2.1 vs. 1.1, respectively) [17]. This could be due
either to efficient, selective transfer of small peptide fragments
from patient blood through the dialysis membrane or to protease
activity on the material in the dialysis circuit, due to enzymes
transferred from blood.
Our search focused on proteins removed from the patients that
could not be detected in the albumin control extracts. Other
proteins that are originally in the albumin solution may also be
removed from blood during the treatment. Identification of these
proteins would require the use of isobaric tag for relative and
absolute quantitation (iTRAQ) [21] labeling or other similar
strategies for semi-quantitative analysis, to detect differences in
protein concentrations between samples. Our approach uses a
rapid and simple label-free method for characterizing proteins
whose concentration considerably changes after dialysis.
The set of proteins that were unique to the extract derived from
patient treatment was richer in proteins of low molecular weight
than the set of proteins identified in albumin control samples [17]
or those expected from the plasma proteome database (http://
plasmaproteomedatabase.org) (Figure 5A). A large fraction of
these proteins (41%) corresponds to small molecules, with a
molecular mass below 20 kDa, that were present in relatively high
Table 2. Peptides and proteins monitored by SRM (Full data in Table S3).
Protein Mr (KDa) Monitored Peptide Sample Detected
(1)
CP
Alpha-1B-glycoprotein 54.3 SWVPHTFESELSDPVELLVAES X X
Serum albumin 69.4 LVNEVTEFAK X X
AVMDDFAAFVEK X X
DYLSVVLNQLCVLHE X X
Apolipoprotein A-II 11.2 EPCVESLVSQYFQTVTDYGK X X
KAGTELVNFLSYFVELGTQPATQ X X
Neutrophil defensin 1 10.2 EPLQARADEVAAAPEQIAADIPEVVVSLAWDESLAPK - X
ADEVAAAPEQIAADIPEVVVSLAWDESLAPK - X
Alpha-2-HS-glycoprotein 39.3 ISRAQLVPLPPSTYVE X X
Fibrinogen alpha chain 95.0 TFPGFFSPMLGEFVSETESR - X
FDTASTGKTFPGFFSPMLGEFVSETESR - X
Pancreatic prohormone 10.4 AQGAPLEPVYPGDNATPEQMAQYAADLRR - X
Serum amyloid A 13.5 SGKDPNHFRPAGLPEKY - X
Secreted Ly-6/uPAR-related protein 1 11.2 CKPEDTACMTTLVTVEAEYPFNQSPVVTR - X
SCSSSCVATDPDSIGAAHLIFCCFRDLCNSEL - X
Transthyretin 15.9 YTIAALLSPYSYSTTAVVTNPKE X X
ALGISPFHEHAEVVFTANDSGPR X X
(1)Detected peptides in control albumin (C) and patient-derived (P) extracts.
doi:10.1371/journal.pone.0021850.t002
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with high sequence coverage and/or a high number of different
peptides). This was a direct reflection of the filtering effect of the
50 KDa pore-size dialysis membrane. This group includes HNP-1,
SLURP1, matrix Gla protein or C-C motif chemokine-14.
Twenty-one proteins (such as plasminogen, granulins, cadherin-2
or extracellular matrix protein 1) with a molecular weight above
50 kDa were also identified. Many of the peptides identified for
these proteins did not show tryptic or GluC cleavage at the N- or
C-terminus as would be expected from our sample treatment. For
example, in the case of fibrinogen, more than 50% of the identified
sequences (36 out of 58) did not show tryptic or GluC cleavage.
These sequences could correspond to protein fragments dialyzed
from blood and in fact, five of the peptides detected had previously
been reported as free peptides in human blood (FIBA peptides 24–
35, 22–35, 21–35, 20–35, 605–622) [22], [23], [24]. One of these
corresponds to fibrinopeptide A, a known cleavage product of the
protein. In the case of complement C4 A/B, a high-molecular-
weight protein (192 kDa), two of the four sequences detected
corresponded to fragments that are not tryptic- or GluC-derived
and one of the tryptic fragments had previously been reported as a
free protein fragment in blood.
In addition, many of these high-molecular-weight proteins
(complement C4-A/B, extracellular matrix protein 1 or polymeric
immunoglobulin receptor) were identified with low coverage,
although the sequences that justify the assignation were detected
with a high number of counts. The number of counts for a peptide
(the times it was detected by MS) is related to its abundance in the
sample [25]. Furthermore, these sequences could be concentrated
in particular regions of the full protein sequence. For example, for
Figure 2. Ion chromatograms for several peptide targets in
control human serum albumin (HSA) and patient-derived
(MARS) extracts (x-axis range of 8 min). The following SRM
transitions were monitored: 1217.5R1298.2, 1441.8 (SLURP1),
1304.4R1739.6, 1080.5, (HNP-1), 1236.6R1183.5, 1515.5 (A1BG) and
1192.9R1969.5, 1683.5 (APOA2) (dotted and solid lines, respectively).
doi:10.1371/journal.pone.0021850.g002
Figure 3. Confirmation of SLURP1 and HNP-1 by Western blot.
Lanes 1, 2, 4 and 5 are patients with resistant pruritus; Lane 3 is a
patient with Wilson’s disease. Lane 6 corresponds to the untreated
albumin-derived extracts.
doi:10.1371/journal.pone.0021850.g003
Figure 4. Detection of SLURP1 in serum by Western blot. Lane 1,
positive control; Lanes 2 and 4, serum from healthy people; Lanes 3 and
5, patients with cholestasis and pruritus. The graph represents the
normalized Western blot intensities of SLURP1 in four groups: healthy
people, patients with cholestasis and pruritus (Chol_P), patients with
cholestasis without pruritus (Chol_NP), and patients with cholestasis
and pruritus who were taking rifampicin (Chol_P+Rif).
doi:10.1371/journal.pone.0021850.g004
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from the full protein, we detected only a set of 3 nested peptides
covering a zone of 25 aa (1% of the protein) but with a total count
of 16 (14+1+1) (Table S1).
Overall, and although it is possible for proteins of non-globular/
irregular shapes to pass through membranes with a pore size
smaller than its specified MWCO, our data suggest that most of
these identifications correspond to sequences derived from protein
fragments and not from the full-length protein sequence.
The set of proteins identified only in albumin after dialysis was
significantly enriched in proteins with disulfide bonds (DAVID
[26], [27] search, fold enrichment=3.2, p=2.5E-7) when
compared with the proteins in the plasma proteome (http://
plasmaproteomedatabase.org). It is interesting to note that a
similar enrichment in proteins with disulfide bonds (3.18-fold,
p=2.33E-32) is found in the components of the albuminome
described in previous work [19], [17]. Whether these two
observations are related and could reflect albumin-affinity-driven
transport processes through the MARS membrane is difficult to
ascertain from our current data. Additionally, many of these
proteins (60%) were found to be interrelated in a STRING (Search
Tool for the Retrieval of Interacting Genes/Proteins) [28] analysis,
which indicates that they could interact directly or indirectly with
albumin (Figure S1). This finding is consistent with the importance
of affinity factors in the MARS dialysis process and is in
accordance with some hypotheses that explain the MARS effect
as a consequence of albumin binding abilities [29].
This set of proteins is significantly enriched in receptor-binding
proteins and in proteins that are involved in the inflammatory
response (Table S4). Some of the identified proteins show cytokine
activity (SLURP1, platelet-derived growth factor subunit A or C-C
motif chemokine 15) or are related to the response to wounding
(serum amyloid A protein, fibrinogen alpha chain or complement
factor D). Secreted proteins were overrepresented (.60%) in the
collection of MARS dialyzed proteins in comparison with the
distribution expected from the human plasma database. This bias
is also observed in the set of proteins found in commercial albumin
preparations (Figure 5B).
The capture of the biologically relevant proteins HNP-1 and
SLURP1 by MARS was confirmed by Western blot. Interestingly,
SLURP1 was not detected in the patient with Wilson’s disease,
which suggests that its presence could be disease-dependent
(Figure 3). Whether SLURP1 is over-expressed in patients with
pruritus or under-expressed in the Wilson patient cannot be
derived from our data.
SLURP1 is a protein with cytokine activity, which modulates
the nicotinic acetylcholine receptor in the presence of acetylcho-
line [30]. Acetylcholine is related to skin diseases; specifically, it
has been described as an inducer of itching in patients with atopic
eczema [31]. It has also been suggested that SLURP1 regulates the
function of keratinocyte through the cholinergic pathways [32].
SLURP1 has been found to be over-expressed in patients with Mal
de Meleda, which is a rare autosomal recessive palmoplantar
keratoderma [33].
The quantification of SLURP1 in serum from healthy
individuals and patients revealed no statistically significant
differences between patients with or without pruritus (Figure 4).
However, significant differences were found between patients and
healthy people. SLURP1 was overrepresented in patients with
cholestasis. A subgroup of the patients with pruritus was treated
with rifampicin, a bactericidal antibiotic drug used in the
treatment of cholestatic pruritus. This subgroup showed lower
levels of SLURP1 than the group of patients with pruritus who
were not receiving the drug. The therapeutic action of rifampicin
against pruritus has been described as mediated by the nuclear
receptor pregnane X (PXR). PXR activates many genes involved
in bile acid biosynthesis, detoxification and transportation [34].
Our data suggest that rifampicin could also diminish SLURP1
levels. Further studies with more patients would be needed to
confirm such a hypothesis and to establish the mechanisms
involved.
In this study, we demonstrated the usefulness of a simple
method based on targeted mass spectrometry for characterizing
proteins trapped during albumin dialysis in a MARS system. The
mechanism of MARS treatments and the set of molecules removed
by this system were little known until now. Proteins removed by
MARS share some structural and biological characteristics, such
as their low molecular weight or their affinity for albumin. Some of
these molecules have important biological functions and their
removal could be related either to therapeutic effects or to possible
adverse effects associated with albumin dialysis. The information
reported here constitutes a unique collection of proteins captured
by MARS. The study aimed to contribute to the understanding of
the effects of albumin dialysis, by assessing potentially disease-
relevant molecules removed under the real conditions that occur
during treatment. In this respect, we have shown that SLURP1,
one of the proteins removed by MARS from patients’ blood, is
overrepresented in serum from patients with cholestasis.
Materials and Methods
Patients and samples
The study protocol conforms to the ethical guidelines of the
Declaration of Helsinki and was approved by the ethics committee
Figure 5. Mass and location distribution of proteins unique to
MARS extracts after patient treatment, in comparison with
proteins in commercial albumin and in the human plasma
database.
doi:10.1371/journal.pone.0021850.g005
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to participate in the study.
The study was performed with samples taken from blood and
MARS SAX cartridges from four patients with cholestasis and
resistant pruritus (two patients with primary biliary cirrhosis, one
patient with autoimmune hepatitis and one with liver graft
rejection) and one patient with a neurologic form of Wilson’s
disease with no liver involvement who was treated to remove
circulating copper. Serum samples from 27 patients with PBC and
10 healthy subjects were also taken and stored at 280uC for
subsequent Western blot analysis to validate some of the results of
the proteomic analysis of the compounds adsorbed in the MARS
SAX cartridge.
Albumin dialysis treatment
ECAD was performed with a MARS
TM system using a constant
flow of 20% human serum albumin (Grifols, Barcelona, Spain) in
the extracapillary compartment, as described before [8]. A total
volume of 600 mL of the albumin solution was used for each
treatment and recirculated for 7 h. After the treatment, the SAX
column was removed and stored at 4uC until analysis.
Control sample preparation
Control samples were prepared by recirculating control
albumin through a SAX column. For this purpose, a 14-cm
long62.6-cm-i.d. Econo-Pac polypropylene column (20 mL)
provided with a frit was filled with 20 mL of resin obtained from
a MARS SAX cartridge (diaMARSH IE250, kindly provided by
Gambro, Hechingen, Germany). This support is a strong anion
exchange (SAX) resin based on cholestyramine. Then, 50 mL of
commercially available HUMAN ALBUMIN GRIFOLSH 20%
solution w/v were recirculated for 6–7 hours at ca. 30 mL/h. The
column was stored for a maximum of 16 h at 4uC before the
peptides and proteins bound to the support were extracted.
Recovery of compounds bound to the SAX support
The overall procedure used for peptide and protein identifica-
tion is depicted in Figure 1. Briefly, twenty milliliters of SAX resin
removed from the MARS cartridges after treatment was placed in
20 mL Econo-Pac columns. In parallel, peptides and proteins
absorbed in control and patient-derived supports were extracted.
For this extraction, the corresponding columns were washed in
10 mM ammonium acetate, pH 7, and the adsorbed components
were eluted by a stepwise gradient of ammonium trifluoroacetate
(TFAM, pH 2.5) and ACN (100 mM/5%, 200 mM/5%,
500 mM/5%, 500 mM/20% TFAM/ACN). Six fractions of
30 mL each were collected.
Sample preparation, protein identification and data
analysis
The protein extract derived from one patient with pruritus and
the control sample were digested and analyzed as described before
[17]. Briefly, two aliquots of the samples were digested with trypsin
(acetylated trypsin from bovine pancreas, Sigma-Aldrich) and
GluC (Staphylococcus aureus protease V8) (Princeton Separations,
Inc., Adelphia, USA), respectively. The resulting peptide samples
were analyzed by multidimensional liquid chromatography
electrospray tandem mass spectrometry (MDLC-ESIMS/MS),
using an Agilent 1200 HPLC (Agilent Technologies, Santa Clara,
CA) system coupled to a linear LTQ ion trap equipped with a
microESI ion source (ThermoFisher, San Jose, CA). Peptides and
proteins were identified as described elsewhere [17], [35].
Selected reaction monitoring analysis
The same MDLC-ESIMS/MS setup as described above was
used for SRM analyses. For each of the targeted peptides, the two
most intense fragment ions observed in the previous MS/MS
analyses were selected for monitoring in the SRM analysis. Ions
corresponding to the loss of water from the precursor ion were not
taken into account in the selection. The acquisition time for each
transition was restricted to a 5–10 min window. Other parameters
were: scan time for each SRM event, 3 microscans; maximum
injection time, 10 ms; parent ion isolation window, 3 m/z; collision
energy, 45%. Collected data on SRM-transitions were evaluated by
QualBrowser in Xcalibur 2.0 (ThermoFisher, San Jose, CA).
Western blot validation
Protein extracts obtained from the SAX MARS cartridges from
the four patients with pruritus and the one with Wilson’s disease
were analyzed by Western blot to confirm the presence of secreted
Ly-6/uPAR-related protein 1 (SLURP1) and neutrophil defensin
1 (HNP-1), two of the relevant peptides identified by the proteomic
analysis. Moreover, SLURP1 was also assessed in serum samples
of patients and healthy controls as follows. To preconcentrate the
protein and eliminate interferences in the Western blot analysis,
200 mL of serum were incubated with SAX resin for 4 hours and
then extracted with 500 mM TFAM 20%ACN. Equal amounts of
SAX-eluted protein were loaded onto a 15% acrylamide:bisacry-
lamide gel (MiniProtean, BioRad), and blotted onto polyvinylidene
difluoride membranes (Immobilon-P membrane, PVDF, 0.45 mm,
9c m 66 cm). The proteins were transferred to the membrane at
100 V for 30 min.
The PVDFblotswereincubatedfor1 hourwithblocking solution
(5% milk, Nestle ´ Sveltesse calcium in PBS). Then, three parallel
overnight incubations were carried out with primary antibodies for
HNP-1 (goat polyclonal HNP C-19, Santa Cruz Biotechnology,
Santa Cruz, CA, USA, diluted 1:100), SLURP1 (mouse monoclo-
nal SLURP1, Abcam, Cambridge, UK, diluted 1:200) and A1BG
(rabbit polyclonal A1BG D-17, Santa Cruz Biotechnology, diluted
1:400). The three PVDF membranes were washed three times in the
blocking solution, incubated with the diluted secondary antibodies
for 2 h (anti-goat IgG-HRP, dil 1:10,000, AbMo rabbit anti-mouse
dil. 1:300, goat anti-rabbit IgG HRP dil 1:10,000, Santa Cruz
Biotechnology) and washed twice in PBS. Staining was then
visualized using the SuperSignal West Pico Chemiluminescent
Substrate 1:1 (ThermoFisher, San Jose, CA, USA).
Supporting Information
Figure S1 Interaction network for 51 of the 60 proteins unique
to the MARS extracts after patient treatment that were available
in the STRING database. Thirty proteins were found linked at the
medium confidence level (score 0.4). Albumin is indicated as ALB
(down, center-right).
(TIF)
Table S1 Complete peptide data set identified by Bioworks and
PEAKS.
(XLS)
Table S2 Data set of proteins mapped by the identified peptides.
(XLS)
Table S3 Peptides and proteins monitored by SRM. Retention
times and SRM transitions.
(XLS)
Table S4 Gene Ontology analysis of the protein set unique to
the MARS-derived extracts (DAVID [26], [27]).
(XLS)
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